This listing of claims will replace all prior versions, and listings, of claims in the application:

## **LISTING OF CLAIMS:**

## 1. – 8. (Canceled)

**9.** (**Currently Amended**) A method for treating an inflammatory component of a disease selected from cystic fibrosis, idiopathic lung fibrosis and fibrosing alveolitis, which method comprises administering, via inhalation, a formulation wherein the active substance consists of a therapeutically effective amount of a salt of tiotropium, and, optionally, physiologically acceptable excipients, and wherein the salt of tiotropium provides an anti-inflammatory activity.

## 10. (Canceled)

- 11. (Previously presented) The method as recited in claim 9 wherein the tiotropium salt has an anion selected from chloride, bromide, iodide, methanesulphonate, paratoluenesulphonate and methylsulphate.
- **12.** (**Previously presented**) The method as recited in claim 11 wherein the anion of the tiotropium salt is methanesulphonate, chloride, bromide or iodide.
- **13.** (**Previously presented**) The method as recited in claim 12 wherein the anion of the tiotropium salt is methanesulphonate or bromide.
- **14.** (**Previously presented**) The method of claim 9, wherein the salt of tiotropium is administered via inhalation in a formulation selected from powders for inhalation, metered-dose aerosols containing propellant gas and propellant-gas-free inhalable solutions.
- 15. (Previously presented) The method of claim 14, wherein the formulation is an

inhalable powder which contains the tiotropium salt in admixture with a suitable physiologically acceptable excipient selected from monosaccharides, disaccharides, oligo- and polysaccharides, polyalcohols, salts, and mixtures thereof.

- **16.** (**Previously presented**) The method of claim 14, wherein the formulation is an inhalable aerosol containing a propellant gas, which contains the tiotropium salt in dissolved or dispersed form.
- **17.** (**Previously presented**) The method of claim 16, wherein the propellant gas is a hydrocarbon or halohydrocarbon gas.
- **18.** (**Previously presented**) The method of claim 16, wherein the propellant gas is n-butane, isobutane, or a fluorinated methane, ethane, propane, butane, cyclopropane or cyclobutane.
- **19.** (**Previously presented**) The method of claim 16, wherein the propellant gas is TG134a, TG227 or a mixture thereof.
- **20.** (**Previously presented**) The method of claim 16, wherein the inhalable aerosol further comprises one or more other ingredients selected from co-solvents, stabilizers, surfactants, antioxidants, lubricants and pH adjusters.
- **21.** (**Previously presented**) The method of claim 14, wherein the formulation is a propellant-free inhalable solution which further comprises a solvent selected from water, ethanol or a mixture of water and ethanol.
- **22.** (**Previously presented**) The method of claim 21, wherein the pH of the propellant-free inhalable solution is 2 7.

- **23.** (**Previously presented**) The method of claim 21, wherein the propellant-free inhalable solution further comprises a co-solvent which contains hydroxyl groups or other polar groups.
- 24. (Canceled)
- **25.** (**Previously presented**) The method of claim 23, wherein the cosolvent is an alcohol or glycol.
- **26.** (**Previously presented**) The method of claim 23, wherein the propellant-free inhalable solution further comprises at least one surfactant, stabilizer, complexing agent, antioxidant, preservative, flavoring, pharmacologically acceptable salt or vitamin.
- **27.** (**Previously presented**) The method of claim 14, wherein the formulation further comprises, as complexing agent, editic acid or a salt of editic acid.
- **28.** (**Previously presented**) The method of claim 14, wherein the formulation further comprises, as complexing agent, sodium edetate.
- **29.** (**Previously presented**) The method of claim 21, wherein the propellant-free inhalable solution contains only benzalkonium chloride and sodium edetate in addition to the active substance and the solvent.
- **30.** (**Previously presented**) The method of claim 21, wherein the propellant-free inhalable solution is a concentrate or a sterile inhalable solution ready for use.
- 31. (Previously presented) The method as recited in claim 12 wherein the anion of the tiotropium salt is bromide.
- **32.** (**Currently Amended**) The method of claim 9, wherein the <del>disease treated is</del> inflammatory component of cystic fibrosis is treated by the anti-inflammatory activity of the salt

of tiotropium.